Multiple Biomarkers in Undiagnosed Pleural Effusion
Evaluation of Multiple Biomarkers in Serum and Pleural Fluid to Estimate the Probability of Cancer in Patients Presenting With an Undiagnosed Pleural Effusion
Sponsor: Fujirebio Diagnostics, Inc.
Terminated
The study was terminated on completion of the Pilot Study phase.
Other terminated trials from Fujirebio Diagnostics, Inc.
More terminations from Fujirebio Diagnostics, Inc.
Other Pleural Effusion trials with similar outcome
This observational or N/A phase trial investigates Pleural Effusion and Pleural Effusion, Malignant and is currently terminated or withdrawn. Fujirebio Diagnostics, Inc. leads this study, which shows 10 recorded versions since 2006 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Dec 2021 — Jul 2024 [monthly]
Terminated
-
Jan 2021 — Dec 2021 [monthly]
Terminated
-
Nov 2020 — Jan 2021 [monthly]
Terminated
▶ Show 5 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Terminated
-
May 2018 — Jun 2018 [monthly]
Terminated
-
Apr 2018 — May 2018 [monthly]
Terminated
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Terminated NA
-
Jan 2017 — Aug 2017 [monthly]
Terminated NA
First recorded
Mar 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fujirebio Diagnostics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .